Literature DB >> 20399854

Long-term genistein treatment of MCF-7 cells decreases acetylated histone 3 expression and alters growth responses to mitogens and histone deacetylase inhibitors.

Kiran Jawaid1, Smiley R Crane, Jennifer L Nowers, Michael Lacey, Saffron A Whitehead.   

Abstract

Defects in epigenetic regulation of gene transcription play an important role in carcinogenesis of the breast and other tissues. The two most widely studied epigenetic changes are DNA methylation and acetylation of histone proteins and inhibition of these processes inhibits growth in breast cancer cell lines. These data coupled with the evidence that fetal and neonatal exposure to oestrogenic substances may lead to epigenetic changes that predispose or protect against the development of breast cancer in later life formed the basis for this study. Three histone deacetylases, valproic acid (VPA), trichostatin A (TCA) and apicidin dose-dependently inhibited basal growth in MCF-7 and MDA-MB-231 as well as the growth promoting effects of oestradiol (E(2)) and epidermal growth factor (EGF) in MCF-7 cells. The growth inhibitory responses to the DNA methyl transferase inhibitor, 5-aza-2'deoxycytidine (decitabine) were weak. HDACi's reduced the protein levels of pro-caspase 9 and cyclin D1, whereas decitabine had no effect. Long-term genistein treatment (LTGT) of MCF-7 cells markedly reduced the basal expression of acetylated histone 3 (H3) and the effects of HDACi's on increasing the levels of acetylated H3 protein. However, this was not correlated with a reduced expression of total H3 except after a high dose of VPA. LTGT inhibited growth of MCF-7 cells and the mitogenic responses to E(2) and EGF. The growth inhibitory responses to HDACI's in the presence of E(2) and EGF was significantly reduced in LTGT cells compared to control MCF-7 cells and there was evidence that LTGT maintained the protein levels of pro-caspase 9 in the presence of HDACi's. This study provides further evidence that oestrogenic substances can induce significant epigenetic changes to alter the dynamics of growth in breast cancer cell lines. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20399854     DOI: 10.1016/j.jsbmb.2010.04.007

Source DB:  PubMed          Journal:  J Steroid Biochem Mol Biol        ISSN: 0960-0760            Impact factor:   4.292


  6 in total

Review 1.  Phytoestrogens and prevention of breast cancer: The contentious debate.

Authors:  Iqra Bilal; Avidyuti Chowdhury; Juliet Davidson; Saffron Whitehead
Journal:  World J Clin Oncol       Date:  2014-10-10

Review 2.  Endocrine disruption of the epigenome: a breast cancer link.

Authors:  Kevin C Knower; Sarah Q To; Yuet-Kin Leung; Shuk-Mei Ho; Colin D Clyne
Journal:  Endocr Relat Cancer       Date:  2014-03-12       Impact factor: 5.678

3.  Does consuming isoflavones reduce or increase breast cancer risk?

Authors:  Maria Bondesson; Jan-Ake Gustafsson
Journal:  Genome Med       Date:  2010-12-21       Impact factor: 11.117

Review 4.  Impact of soy isoflavones on the epigenome in cancer prevention.

Authors:  Maria Pudenz; Kevin Roth; Clarissa Gerhauser
Journal:  Nutrients       Date:  2014-10-15       Impact factor: 5.717

Review 5.  Phytochemicals Targeting Estrogen Receptors: Beneficial Rather Than Adverse Effects?

Authors:  Sylvain Lecomte; Florence Demay; François Ferrière; Farzad Pakdel
Journal:  Int J Mol Sci       Date:  2017-06-28       Impact factor: 5.923

6.  Genistein Promotes Proliferation of Human Cervical Cancer Cells Through Estrogen Receptor-Mediated PI3K/Akt-NF-κB Pathway.

Authors:  Hai-Hong Chen; Shu-Ping Chen; Qiu-Ling Zheng; Shao-Ping Nie; Wen-Juan Li; Xiao-Juan Hu; Ming-Yong Xie
Journal:  J Cancer       Date:  2018-01-01       Impact factor: 4.207

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.